Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. , and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

The acquisitions of Ambry Genetics and Deep 6 AI are expected to have contributed to Tempus AI's strategic expansion during the first quarter of 2025. The acquisition of Ambry Genetics ...

Major acquisitions and partnerships have played a key role in Tempus AI’s market growth, solidifying its position in healthcare AI. The Ambry Genetics acquisition expanded its genomics division ...

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

Tempus AI reports mixed fourth-quarter financial results. JPMorgan analyst Rachel Vatnsdal downgrades Tempus AI from Overweight to Neutral following the company's quarterly results. Get stock ...